MNKD Mannkind Corp

$MNKD Update: I've have been on Afrezza for just a bit over a year now. Here is my latest A1C (5.8) and trend over the last year and a half. For all the naysayers out there (most of them I have blocked) you have no idea what you are talking about when bashing Afrezza. Many of us already believed in Afrezza & Technosphere by investing in the company many, many years ago but I now have first hand evidence that it is the REAL DEAL and everything Al Mann said was true.

$MNKD I am about as long as anyone on this board. That being said I am as frustatrated as most long term longs on this board. By earning call Afrezza will have been approved 6 months and Furocyx almost 4 months. Granted that is not a a significant amount of time to fully guage success or failure. However, we should have a glimpse of adoption of Afrezza in peds. We had superb study results backed by a plethora of peds endocrinologist supporting inhaled well over MDI at the very least. How about gestational diabetes trial that expected completion in July, have we heard anything? Dominic Marasco, a colleague and friend of the CEO, was hired in January of 2025. Having 16 months to prepare for the peds launch and 6 months into the launch we should have significant data on how things are going. Dont get me wrong, I think the pipeline is great, the synergism with UTHR, and the potential synergism that could develop with a BP partner are all there. Execution must follow and soon.

$MNKD Stock price sucks. Can't argue that. If you believe Mannkind can and will sell a lot of Furoscix AI and get Afrezza moving forward with PEDs, it's a no brainer but to take advantage of a lower share price. If you think Mike's gonna fail, you should remove your funds from this stock before the next ER drops and find a company more suited towards your expectations. It's not a hard decision. I will stick around as I believe the current management is on track to make the cretin's look dumb. Just saying...... ENJOY YOUR WEEKEND FOLKS! 👍

$MNKD Short Interest 09/30/26: 26,157,578 (SP: $3.90) Days to cover: 4.436382 Short Interest 09/15/26: 29,398,550 (SP: $3.56) Change: -3,240,972

$MNKD FWIW from AI. Hopefully we see the fruits soon. • Concentrated Prescribers: Roughly 80% of pediatric diabetes care is managed by fewer than 1,000 specialists located across just 50 academic medical centers. • Built-in Familiarity: Approximately half of the physicians at these major academic centers directly participated in the INHALE-1 clinical trials. This means a massive portion of the core decision-makers already have hands-on experience prescribing and monitoring Afrezza in kids.

$MNKD Order Number: 1071 Order type: Buy Security: MNKD Term: Day Price type: Market Execution price: $3.405 Quantity: 2000

$MNKD Kuka…spot on, Brother. Past time to sell the company as a whole or in parts $33 a share is Great but, at this point, I’d take $25 a share and run like my pantaloons were on fire! 🔥 Red wine 🍷 “cheers” to all us long time Mannkinders T.

$MNKD MNKD Board of Directors made a huge mistake appointing Mike as a first time CEO with no experience to lead the company providing him with on the job training. In 2016 when MNKD got back Afrezza rights from Sanofi with 100% ownership and control of Alfred Mann innovative creations at MNKD FDA approved Afrezza, Technosphere DPI, Dreamboat & Cricket and Manufacturing Facility, they initially were on the right track when they hired Duane Desisto as MNKD new CEO to replace Hakan Edstrom, which fell apart when MNKD had to withdraw the offer due to a non-compete agreement Duane had with his former company Insulet. MNKD then turned to their CFO Matt Pfeffer appointing him CEO also a first time CEO, who did not remain in the job very long replacing him with Mike as CEO. After Al Mann stepped down as CEO, MNKD had 3 inexperienced CEO running the company Edstrom, Pfeffer & Castagna all first time CEO's and in the last 10 years BOD and Management have become rich while Shareholders have not

$MNKD NATE, I’ve been making money buy investing in good companies with good CEOs…as one of many examples look at NAT which I bought in the low twos…a GREAT CEO who buys shares in his own company . MNKD should be killing it…but I can only trade it becuase the overpaid CEO with a HUGE staff in this company kills the opportunity for investors

$MNKD Nate..the only FACT that counts is the share value…period!! If a coach’s team loses…even though he may be a good coach …the coach gets fired THE ONLY FACT IS THE SHARE PRICE WITH ALL OF THE ADVANCEMENTS AND APPROVALS IS $3.25!! People invest in companies to make money when the companies share price goes up. And what the hell is this interweb stuff ??

$MNKD I think many here forget that the technosphere platform is the Golden Goose. That technology opens the door for hundreds of other molecules. The current products are just a fraction of the potential. BIG Pharma knows this....

$MNKD Another massive disaster year. Not sure how this CEO still has a job. If the next ER is negative EPS, it will likely push the SP deep into the 2's. The cash crunch will translate into a cash crunch in 2027, especially if they need to fund pipeline work then. This will cause further dilution. $3 will become the new $6. CEO will proabably sell some more of his free share before the end of the year, my guess is around $2.80. Without UTHR (or other BP) buyout/partner, this sinks like s stone.

$MNKD It has been a long time since we popped a dollar plus in a day…just saying. Cheers to better days ahead my Mannkind brothers and sisters!🍸

$MNKD This CEO has been a disaster, he needs to go. Ask yourself, what percentage of your ownership did you lose to his horrible decisions and exorbitant compensation? How much of your ownership did he waste on V-go? How much on botching Afrezza commercialization, and delivering the peds study nearly a decade late? How much went right into his pocket, in free shares that he has already sold? How much will you lose on the Furoscix disaster, after SC saying in their own 10K's that it was a money losing product? How many times can you allow yourselves to be duped? #FireMikeNow #Dupest

$MNKD MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

$MNKD After trading in double digits Mannkind stock price tanked in January 2016 and has been stuck in a trading range below $5 for the past 10 years and 10 months with Mannkind shareholders seeing no value created and the stock price down 95% from its all time high hit in 2014. Something needs to change !

$MNKD KukaAi pontificates that tutes are buying hand over fist. Why isn't he pointing out that Mannkind's management and BoD rarely buy a share with their own money?

$MNKD It reminds of years ago when the stock was down 10 cents a day for weeks on end for no reason at all. There are few evil companies that have a hatred for MNKD: GS, BofA, etc. and seem to continuously suppress the stock.

$MNKD a lot of false information on here. Institutional ownership over last 4 years. Chart speaks for itself.

$MNKD Nate, this is for you 😘 We need a better CEO. We cannot expect this company to survive and grow just because our “competitor” lost a court case or because something went wrong for someone else. That’s not a strategy. Personality, willingness, attitude, energy, and leadership all reflect directly on the company. And honestly, when I look at Mike, I see someone who, in my opinion, simply does not deserve that role. We need leadership that inspires confidence, creates momentum, and actually makes investors believe in the future of this company. Repeat with me: we need a better CEO.